Skip to content
Screener

Bicara Therapeutics BCAX Business Segments — Total Operating Expenses

Similar metrics at other companies

Absci Corporation logo
ABSISegment One — Total Operating Expenses
$31.06M+7.4%
Idexx Laboratories logo
IDXXCAG segment revenue — Total Operating Expenses
$360.15M+17.4%
Idexx Laboratories logo
IDXXLPD segment revenue — Total Operating Expenses
$360.15M+17.4%
Erie Indemnity Company logo
ERIEManagement Operations — Total Operating Expenses
$845.12M+0.8%
Faraday Future Intelligent Electric logo
FFAIAIEV — Total Operating Expenses
$20.01M-64.6%
Faraday Future Intelligent Electric logo
FFAIAIXC — Total Operating Expenses
$4.52M+149%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.81B+217%
Enterprise value$1.49B+1,000%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033429
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Professional fees3,5601,504
Facility costs, IT, office expense and other1,2191,119
Total general and administrative expenses12,7427,455
Total operating expenses60,24241,788
Operating loss(60,242)(41,788)
Interest income4,0835,014
Total other income4,0835,014
Net income before losses(56,159)(36,774)

Item 1. Financial Statements (Unaudited)

FAQ

What is Bicara Therapeutics's business segments — total operating expenses?
Bicara Therapeutics (BCAX) reported business segments — total operating expenses of $60.24M in Q1 2026.
How has Bicara Therapeutics's business segments — total operating expenses changed year-over-year?
Bicara Therapeutics's business segments — total operating expenses increased by 44.2% year-over-year, from $41.79M to $60.24M.
What is the long-term trend for Bicara Therapeutics's business segments — total operating expenses?
Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — total operating expenses has grown at a 97.5% compound annual growth rate (CAGR), from $39.89M to $155.6M.
What does business segments — total operating expenses mean?
The sum of all costs incurred in the normal course of business, including research and development, clinical operations, and general administrative overhead. This metric is a key indicator of the company's total cash burn rate and operational scale.

Ask your AI about Bicara Therapeutics's business segments — total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude